ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 321,72
-0,02%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. XOMA Corporation (XOMAP)

  7. XOMA Corporation (XOMAP) Actualités

XOMAP

XOMA (XOMAP)

XOMA Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:XOMAP
DateHeureSourceTitreSymboleSociété
30/05/202422h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XOMAPXOMA Corporation
17/05/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XOMAPXOMA Corporation
14/05/202413h30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQNASDAQ:XOMAPXOMA Corporation
09/05/202413h35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XOMAPXOMA Corporation
09/05/202413h30GlobeNewswire Inc.XOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAPXOMA Corporation
30/04/202413h30GlobeNewswire Inc.XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%NASDAQ:XOMAPXOMA Corporation
25/04/202413h30GlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAPXOMA Corporation
03/04/202415h00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAPXOMA Corporation
21/03/202412h30GlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAPXOMA Corporation
19/03/202421h05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAPXOMA Corporation
11/03/202411h56Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:XOMAPXOMA Corporation
08/03/202422h34Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:XOMAPXOMA Corporation
08/03/202413h30GlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAPXOMA Corporation
04/03/202423h24Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:XOMAPXOMA Corporation
28/02/202413h30GlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAPXOMA Corporation
16/02/202414h00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:XOMAPXOMA Corporation
18/01/202414h30GlobeNewswire Inc.XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionNASDAQ:XOMAPXOMA Corporation
16/01/202423h22Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:XOMAPXOMA Corporation
11/01/202422h05GlobeNewswire Inc.FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxNASDAQ:XOMAPXOMA Corporation
08/01/202413h30GlobeNewswire Inc.XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of DirectorsNASDAQ:XOMAPXOMA Corporation
02/01/202413h30GlobeNewswire Inc.XOMA Announces Stock Repurchase Program of up to $50 MillionNASDAQ:XOMAPXOMA Corporation
19/12/202313h30GlobeNewswire Inc.XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesNASDAQ:XOMAPXOMA Corporation
07/11/202313h30GlobeNewswire Inc.XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAPXOMA Corporation
31/10/202312h30GlobeNewswire Inc.XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAPXOMA Corporation
06/09/202313h30GlobeNewswire Inc.XOMA to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:XOMAPXOMA Corporation
08/08/202313h30GlobeNewswire Inc.XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization StrategyNASDAQ:XOMAPXOMA Corporation
24/06/202300h14GlobeNewswire Inc.XOMA Added to the Russell 2000® and Russell 3000® IndexesNASDAQ:XOMAPXOMA Corporation
22/06/202313h30GlobeNewswire Inc.XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology AssetNASDAQ:XOMAPXOMA Corporation
25/05/202322h34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XOMAPXOMA Corporation
18/05/202323h23Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XOMAPXOMA Corporation
 Showing the most relevant articles for your search:NASDAQ:XOMAP

Dernières Valeurs Consultées

EU
VK
Vallourec
COIN
ETHUSD
Ethereum
EU
ACA
Credit Agricole
COIN
BTCUSD
Bitcoin
NYSE
NKE
Nike
EU
BEL20
Bel 20
EU
LR
Legrand
EU
RI
Pernod Ricard
NYSE
KO
Coca Cola
EU
CAP
Capgemini
EU
MC
Lvmh Moet Hennessy Louis...
EU
ML
Michelin
EU
RNO
Renault
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés